When is sylvant off patent?

When does Sylvant (siltuximab) lose patent protection?

Sylvant is the brand name for siltuximab, a medicine used for certain cases of multicentric Castleman disease. The exact “off-patent” timing depends on which patent(s) and what country you mean, because patent protection and exclusivity rules differ by jurisdiction.

The provided information does not include Sylvant’s patent expiry dates or exclusivity timelines, so I can’t state a specific “off-patent” year without those details.

What do people usually mean by “off patent” for drugs like Sylvant?

Searches for “off patent” can refer to:
- the end of the active compound patent term (when generics/biosimilars may be possible in principle), or
- the end of data/exclusivity periods (when regulators may still restrict approval using existing trial data).

Those dates often differ, so it helps to know which meaning you want.

Which country’s patent expiry date should I look for?

Tell me the country (or region) you care about—such as the US, EU, UK, or Canada—and whether you mean:
- “end of patents” (generic/biosimilar entry could start), or
- “end of exclusivity/data protection.”

With that, I can give the most relevant expected timeline for Sylvant in that jurisdiction.